DK1851239T3 - Replikationsdeficiente RNA-vira som vacciner - Google Patents

Replikationsdeficiente RNA-vira som vacciner

Info

Publication number
DK1851239T3
DK1851239T3 DK06706871T DK06706871T DK1851239T3 DK 1851239 T3 DK1851239 T3 DK 1851239T3 DK 06706871 T DK06706871 T DK 06706871T DK 06706871 T DK06706871 T DK 06706871T DK 1851239 T3 DK1851239 T3 DK 1851239T3
Authority
DK
Denmark
Prior art keywords
cell
iii
dna molecule
genome
replication
Prior art date
Application number
DK06706871T
Other languages
English (en)
Inventor
Wolfgang J Neubert
Sascha Bossow
Sabine Schlecht
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of DK1851239T3 publication Critical patent/DK1851239T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK06706871T 2005-02-11 2006-02-10 Replikationsdeficiente RNA-vira som vacciner DK1851239T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005006388A DE102005006388A1 (de) 2005-02-11 2005-02-11 Replikationsdefiziente RNA-Viren als Impfstoffe
PCT/EP2006/001251 WO2006084746A1 (de) 2005-02-11 2006-02-10 Replikationsdefiziente rna-viren als impfstoffe

Publications (1)

Publication Number Publication Date
DK1851239T3 true DK1851239T3 (da) 2009-05-18

Family

ID=36353666

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06706871T DK1851239T3 (da) 2005-02-11 2006-02-10 Replikationsdeficiente RNA-vira som vacciner

Country Status (23)

Country Link
US (2) US20090041725A1 (da)
EP (2) EP1851239B1 (da)
JP (2) JP5679620B2 (da)
KR (1) KR101279636B1 (da)
CN (1) CN101155826B (da)
AT (1) ATE421529T1 (da)
AU (1) AU2006212385B2 (da)
BR (1) BRPI0607487A2 (da)
CA (1) CA2599036C (da)
DE (2) DE102005006388A1 (da)
DK (1) DK1851239T3 (da)
EA (1) EA015013B1 (da)
ES (1) ES2321651T3 (da)
HK (1) HK1118297A1 (da)
HR (1) HRP20090230T1 (da)
IL (1) IL185147A (da)
MX (1) MX2007009628A (da)
PL (1) PL1851239T3 (da)
PT (1) PT1851239E (da)
RS (1) RS50977B (da)
SI (1) SI1851239T1 (da)
WO (1) WO2006084746A1 (da)
ZA (1) ZA200707216B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005006388A1 (de) 2005-02-11 2006-08-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Replikationsdefiziente RNA-Viren als Impfstoffe
FI2604695T3 (fi) 2007-12-27 2023-02-16 Replikaatiokyvyttömiä arenavirusvektoreita
EP2085479A1 (en) * 2008-01-31 2009-08-05 Institut Pasteur Reverse genetics of negative-strand rna viruses in yeast
EP2434012B1 (en) * 2009-05-18 2017-12-13 National Institute of Advanced Industrial Science And Technology Vector material for creating pluripotent stem cells, and pluripotent stem cell creation method using said vector material
US9365866B2 (en) 2009-06-03 2016-06-14 National Institute Of Advanced Industrial Science And Technology Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same
DE102010018961B4 (de) * 2010-04-23 2012-09-20 Eberhard-Karls-Universität Tübingen Universitätsklinikum Genetisch modifiziertes Paramyxovirus zur Behandlung von Tumorerkrankungen
ES2640113T3 (es) 2011-02-08 2017-10-31 Mie University Método para producir un vector viral para la transferencia génica
JP6757121B2 (ja) * 2011-10-05 2020-09-16 ジェンヴェック エルエルシー シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法
EP2669381A1 (en) * 2012-05-30 2013-12-04 AmVac AG Method for expression of heterologous proteins using a recombinant negative-strand RNA virus vector comprising a mutated P protein
WO2014140301A1 (en) 2013-03-15 2014-09-18 Université De Genève Anti-mycobacterial vaccines
EP2813574B1 (en) * 2013-06-10 2019-02-20 RSV Genius GmbH Semi-live respiratory syncytial virus vaccine
MX367093B (es) * 2013-06-10 2019-08-05 Amvac Ag Vacuna semi-viva del virus sincitial respiratorio.
WO2023227758A1 (en) 2022-05-25 2023-11-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccine with reduced anti-vector antigenicity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1394259A3 (en) 1994-07-18 2004-04-14 Karl-Klaus Prof. Dr. Conzelmann Recombinant infectious non-segmented negative strand RNA virus
ATE470704T1 (de) * 1995-11-01 2010-06-15 Dnavec Research Inc Rekombinantes sendai-virus
WO2003025570A1 (en) * 2001-09-18 2003-03-27 Dnavec Research Inc. Method of examining (-) strand rna virus vector having lowered ability to form grains and method of constructing the same
CN1347453A (zh) 1999-12-10 2002-05-01 由卫生与公众服务部代表的美利坚合众国政府 重组副流感病毒(piv)作为载体提供保护对抗piv及其他人类病原体引起的感染和病症的用途
JP4791651B2 (ja) * 2000-05-18 2011-10-12 株式会社ディナベック研究所 外来遺伝子導入用パラミクソウイルスベクター
JP2004344001A (ja) * 2003-03-07 2004-12-09 Dnavec Research Inc 胚性幹細胞に遺伝子を導入する方法
JP2004357689A (ja) * 2003-06-03 2004-12-24 Dnavec Research Inc 遺伝子導入ベクターの非侵襲的インビボ評価方法
KR100999316B1 (ko) * 2003-06-09 2010-12-10 와이어쓰 엘엘씨 ｃＤＮＡ로부터의 비분절 네가티브 쇄 ＲＮＡ 바이러스의회수를 위한 개선된 방법
DE102005006388A1 (de) 2005-02-11 2006-08-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Replikationsdefiziente RNA-Viren als Impfstoffe

Also Published As

Publication number Publication date
CN101155826B (zh) 2011-10-12
PT1851239E (pt) 2009-04-28
RS50977B (sr) 2010-10-31
CN101155826A (zh) 2008-04-02
AU2006212385A1 (en) 2006-08-17
EA015013B1 (ru) 2011-04-29
CA2599036C (en) 2014-11-04
KR101279636B1 (ko) 2013-06-28
ZA200707216B (en) 2008-05-28
JP5679620B2 (ja) 2015-03-04
EA200701695A1 (ru) 2008-02-28
HRP20090230T1 (en) 2009-05-31
EP1851239B1 (de) 2009-01-21
JP2012213407A (ja) 2012-11-08
CA2599036A1 (en) 2006-08-17
BRPI0607487A2 (pt) 2009-09-08
ES2321651T3 (es) 2009-06-09
AU2006212385B2 (en) 2011-12-15
US20180142256A1 (en) 2018-05-24
US11028409B2 (en) 2021-06-08
PL1851239T3 (pl) 2009-07-31
KR20070110345A (ko) 2007-11-16
US20090041725A1 (en) 2009-02-12
MX2007009628A (es) 2007-11-15
DE502006002711D1 (de) 2009-03-12
WO2006084746A1 (de) 2006-08-17
EP2045260A1 (de) 2009-04-08
SI1851239T1 (sl) 2009-08-31
HK1118297A1 (en) 2009-02-06
IL185147A0 (en) 2007-12-03
EP1851239A1 (de) 2007-11-07
ATE421529T1 (de) 2009-02-15
IL185147A (en) 2011-12-29
DE102005006388A1 (de) 2006-08-24
JP2008529508A (ja) 2008-08-07

Similar Documents

Publication Publication Date Title
DK1851239T3 (da) Replikationsdeficiente RNA-vira som vacciner
Kobayashi et al. An improved reverse genetics system for mammalian orthoreoviruses
AU2005240118B2 (en) Methods and compositions for reducing viral genome amounts in a target cell
Varnavski et al. Stable high-level expression of heterologous genes in vitro and in vivo by noncytopathic DNA-based Kunjin virus replicon vectors
Kneidinger et al. Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery
Kim et al. Multiple shRNAs driven by U6 and CMV promoter enhances efficiency of antiviral effects against foot-and-mouth disease virus
Xie et al. Inhibition of dengue virus 2 replication by artificial micrornas targeting the conserved regions
GB201103167D0 (en) Gene silencing
Rothe et al. Rapid construction of adeno-associated virus vectors expressing multiple short hairpin RNAs with high antiviral activity against echovirus 30
JP2008546399A5 (da)
WO2007149946A3 (en) Composition and methods for expressing reporter molecules in mammalian cells
Hinzman et al. Selection for gene junction sequences important for VSV transcription
de Carvalho et al. Multi-targeted gene silencing strategies inhibit replication of Canine morbillivirus
JP2017000015A (ja) 目的遺伝子の発現誘導可能なウイルスベクター
EP2485745B1 (en) A composition for creating conditional lethality of virus mutants and for eliminating the viability of an eukaryotic cell
WO2007102140A3 (en) A semliki forest virus replication competent vector with enhanced biosafety
AU2015201136B2 (en) Methods and compositions for reducing viral genome amounts in a target cell
Zhu et al. Specific nucleotide changes in the subgenomic promoter region influence infectivity of the sindbis virus
Vanmechelen et al. Development and optimization of a novel T7 polymerase-independent Marburg virus minigenome system
Archambault et al. The intraleader AUG nucleotide sequence context is important for equine arteritis virus replication
Zhang et al. Screening efficient siRNAs in vitro as the candidate genes for chicken anti-avian influenza virus H5N1 breeding
Scott Inhibition of Rift Valley Fever Virus Using RNA Interference Technology
TW200714713A (en) A virus vector for inducing gene inactivation of plants
Patel et al. Reducing Influenza Virus Infection through shRNA-Targeting TMPRSS2 Protease